Capella Scientia Development Study
Capella Scientia (SCDX) Development Study
- Cataract
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Alcon Research
- Enrolment target
- 400
- Started
- 30 July 2025
- Main results due (estimated)
- May 2027
- Study ends (estimated)
- May 2027
- Observational model
- Cohort
- Time perspective
- Prospective
- Sites
- 5 · 1 in India
- First posted
- 23 May 2025
- Registry updated
- 30 October 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- Who they are looking for: Subjects will be recruited from clinical sites located in India, Spain, and the Philippines.
Age groups: adult, older adult. Sampling: non probability sample.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Able to understand and sign an IRB/IEC approved consent form; * Willing and able to attend study visit(s) as required by the protocol; * Consenting age at the jurisdiction of study site; * Other group-specific, protocol required inclusion criteria may apply. Exclusion Criteria: * Women of child-bearing potential; * Unable to fixate due to nystagmus or other eye movement abnormality (e.g., significant strabismus); * Unclear optical media preventing data capture from all devices in the study; * Contraindicated for pupil dilation (e.g., narrow angles, allergies) per investigator's clinical judgment; * Any ocular disease and/or condition that, in the investigator's clinical judgment, may put the subject at significant risk, may compromise study results, or may interfere significantly with the subject's participation in the study; * Other group-specific, protocol required exclusion criteria may apply.
What this study is about
In the sponsor’s own words, from the registry.
This study involves collecting biometry and aberration data using the next generation biometer, Unity DX.
Read the detailed description
In this prospective, noninterventional, single-arm, unmasked, multicenter study, 4 different subject cohorts will be enrolled simultaneously to collect biometry and aberrometry data using Unity DX. This study will be conducted in the US, India, Spain, and the Philippines.
What participants receive
Group 1
Subjects/eyes previously implanted with an Alcon monofocal or multifocal presbyopia correcting IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.
Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer
Group 2
Subjects/eyes with planned implantation of an Alcon monofocal or monofocal toric IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.
Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer
Group 3
Subjects/eyes with with prior refractive surgery such as LASIK or PRK and planned implantation of an Alcon monofocal or monofocal toric IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.
Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer
Group 4
Subjects/eyes with keratoconus, a progressive cornea disorder. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.
Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer
Interventions
Unity DX and SMARTCataract DX (SCDX) BiometerDevice
Unity DX is a CE-marked, noninvasive, noncontact instrument that generates a 3D model of the eye using hyper parallel optical coherence tomography (HP OCT), aberrometry, and topography. The current version of SCDX software will be used in this study.
IOLMaster 700 BiometerDevice
The IOLMaster 700 Biometer is a CE-marked, noninvasive, noncontact instrument that captures optical biometry. Data will be collected using standard clinical assessments.
Argos with Alcon Image Guidance BiometerDevice
The Argos with Alcon Image Guidance biometer is a CE-marked, noninvasive, noncontact instrument that will capture optical biometry. Data will be collected using standard clinical assessments.
What the study measures
Primary outcomes
Manifest Refraction Spherical Equivalent (MRSE)
A manifest refraction (manual refraction) will be performed using a phoropter. The spherical equivalent is calculated by adding the sum of the sphere power with half of the cylinder power. MRSE will be reported in diopters.
Time frame: Group 1 and Group 4: Day 0; Group 2 and Group 3: Screening (Day -30 to Day -1), Day 30 to 60 postoperative, Day 70 to 100 postoperative
Who is running it
- Lead sponsor
- Alcon Research
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Alcon Research
- Data monitoring committee
- No
- US FDA-regulated drug
- No
- US FDA-regulated device
- No
- Sponsor's study ID
- CTK378-E006
Principal II, Clinical Trial Operations, Vision Care
Study director
Alcon Research, LLC
Study sites(5)
Narayana Nethralaya
Bangalore, India
Not yet recruiting
The Eye Institute of Utah
Salt Lake City, Utah, United States
Recruiting
Asian Eye Institute
Makati City, Philippines
Recruiting
Clinica Novovision - Clinica Madrid
Madrid, Spain
Recruiting
Clinica Rementeria
Madrid, Spain
Recruiting
Showing 5 of 5 sites. 4 recruiting, 1 not recruiting and 0 cancelled; 1 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- No
Source: ClinicalTrials.gov record NCT06987474, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.